Arca
Skip to content

Hemophilia

Drug research and approvals for hemophilia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 88 studies of hemophilia are recruiting on ClinicalTrials.gov, Health Canada has authorized 67 drug trials for it since 2013, FDA has 36 approved and 37 open orphan designations naming it, and the EU has 25 authorised medicines for it.

  • Recruiting worldwide: 88
  • Trials authorized in Canada: 67
  • FDA orphan approvals: 36
  • EU medicines: 25

Recruiting Now

Newest start dates first, of 88 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 67; search them all in Canada trials
Aug 18, 2026A multicenter, open-label, single-arm, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of nxt007 prophylaxis…NXT007 (RO7589655)RochePending
Jun 18, 2026A multinational, open-label study to investigate efficacy and safety of denecimig (mim8) in adults with acquired haemophilia aMIM8 / NNC0365-3769Novo NordiskPending
Mar 26, 2026A multicenter, randomized, open-label, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of nxt007 prophylaxis…NXT007 (RO7589655) / ELOCTATE / ADYNOVATE / ESPEROCT / XYNTHA / KOVALTRY / JIVIRochePending
Mar 18, 2026A multicenter, randomized, open label, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of nxt007 prophylaxis…NXT007 (RO7589655) / HEMLIBRA [EMICIZUMAB (RO5534262)]RocheOngoing
Aug 20, 2025An open-label, parallel, phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12…FITUSIRAN (SAR439774)SANOFI-AVENTIS CANADA INCOngoing
May 9, 2025A phase 1 single and multiple dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of sr604 in healthy…SR604EQUILIBRA BIOSCIENCE LLCClosed
Feb 27, 2025A phase 1 b open-label non-randomized study to assess the safety, pk &pd of marstacimab treatment following the discontinuation of emicizumab therapy in…MARSTACIMABPfizerClosed
Dec 12, 2024Synoviiius: prospective interventional study of effectiveness of efanesoctocog alfa prophylaxis on synovial hypertrophy in patients with hemophilia aBIVV001 (EFANESOCTOCOG ALFA)SanofiOngoing
Aug 22, 2024A phase 1/2 dose escalation and expansion study of be-101 for the treatment of adults with moderately severe or severe hemophilia bBE-101BE BIOPHARMAPending
Jul 4, 2024A phase 3, single-arm, open-label, multicenter study of the safety and efficacy of dirloctocogene samoparvovec (spk-8011, adeno-associated viral vector with…DIRLOCTOCOGENE SAMOPARVOVEC (SPK-8011) / CELLCEPT / METHYLPREDNISOLONESPARK THERAPEUTICS INCPending

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 73
Jun 5, 2026Hympavziroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with…Pfizer Inc.Approved
Jul 31, 2025Alhemoroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Novo Nordisk, Inc.Approved
Jul 31, 2025Alhemoroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Novo Nordisk, Inc.Approved
Mar 28, 2025Qfitliafor routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older…Genzyme CorporationApproved
Mar 28, 2025Qfitliaroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with…Genzyme CorporationApproved
Dec 20, 2024Alhemoroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Novo Nordisk, Inc.Approved
Dec 20, 2024Alhemoroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Novo Nordisk, Inc.Approved
Oct 11, 2024Hympavziroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Pfizer Inc.Approved
Apr 25, 2024Beqveztreatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who: Currently use factor IX prophylaxis…Pfizer Inc.Approved
Jun 29, 2023Roctaviantreatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity less than 1 IU/dL) without…BioMarin Pharmaceutical, Inc.Approved
Feb 22, 2023Altuviiioin adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding…Bioverativ Therapeutics, Inc.Approved
Nov 22, 2022HemgenixTreatment of adults with Hemophilia B (congenital Factor IX deficiency) who: currently use Factor IX prophylaxis therapy, or; have current…CSL Behring LLCApproved
Jul 29, 2022RebinynRoutine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital Factor IX deficiency)Novo Nordisk, Inc.Approved
Oct 5, 2021BeneFixRoutine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital factor IX deficiency…Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.Approved
Jun 26, 2020BeneFixRoutine prophylaxis to reduce the frequency of bleeding episodes in patients 16 years of age and older with hemophilia B (congenital factor…Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.Approved

Medicines Authorised in the EU

Newest first; 15 of 25
Dec 13, 2024AlhemoconcizumabNovo Nordisk A/SEMA ↗
Nov 18, 2024HympavzimarstacimabPfizer Europe MA EEIGEMA ↗
Jun 17, 2024Altuvoctefanesoctocog alfa · orphanSwedish Orphan Biovitrum AB (publ)EMA ↗
Feb 20, 2023Hemgenixetranacogene dezaparvovec · orphanCSL Behring GmbHEMA ↗
Jul 15, 2022Cevenfactaeptacog beta (activated)Laboratoire Francais du Fractionnement et des BiotechnologiesEMA ↗
Jun 20, 2019Esperoctturoctocog alfa pegolNovo Nordisk A/SEMA ↗
Nov 22, 2018Jividamoctocog alfa pegolBayer AGEMA ↗
Feb 23, 2018HemlibraemicizumabRoche Registration LimitedEMA ↗
Jan 8, 2018Adynovirurioctocog alfa pegolBaxalta Innovations GmbHEMA ↗
Jun 2, 2017Refixianonacog beta pegolNovo Nordisk A/SEMA ↗
Feb 13, 2017Vihumasimoctocog alfaOctapharma ABEMA ↗
Jan 4, 2017Afstylalonoctocog alfaCSL Behring GmbHEMA ↗
May 12, 2016Alprolixeftrenonacog alfa · orphanSwedish Orphan Biovitrum AB (publ)EMA ↗
May 11, 2016Idelvionalbutrepenonacog alfa · orphanCSL Behring GmbHEMA ↗
Feb 18, 2016Kovaltryoctocog alfaBayer AGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.